Vitamin D and prostate cancer prognosis: a Mendelian randomization study.

Decreased vitamin D levels have been associated with prostate cancer, but it is unclear whether this association is causal. A functional single-nucleotide polymorphism (SNP) in the group-specific component (GC) gene (T > G, rs2282679) has been associated with 25-hydroxy (25-OH) vitamin D and 1.

25 dihydroxy (1 25-OH2) vitamin D levels

To examine the hypothesized inverse relationship between vitamin D status and prostate cancer, we studied the association between this SNP and prostate cancer outcome in the prospective PROCAGENE study comprising 702 prostate cancer patients with a median follow-up of 82 months

GC rs2282679 genotypes were not associated with biochemical recurrence [hazard ratios (HR) 0 91, 95 % confidence interval (CI) 0 73-1 12; p = 0 36], development of metastases (HR 1 20, 95 % CI 0 88-1 63; p = 0 25) or overall survival (HR 1 10; 95 % CI 0 84-1 43; p = 0 50)

A causal role of vitamin D status, as reflected by GC rs2282679 genotype, in disease progression and mortality in prostate cancer patients is unlikely

World journal of urology 2015 Jul 25 [Epub ahead of print]

Olivia Trummer, Uwe Langsenlehner, Sabine Krenn-Pilko, Thomas R Pieber, Barbara Obermayer-Pietsch, Armin Gerger, Wilfried Renner, Tanja Langsenlehner

Division of Endocrinology and Metabolism, Department of Internal Medicine, Medical University of Graz, Graz, Austria

PubMed